MX2016006052A - Pirido[4,3-b]pirazin-2-carboxamidas como agentes neurogenicos para el tratamiento de trastornos neurodegenerativos. - Google Patents
Pirido[4,3-b]pirazin-2-carboxamidas como agentes neurogenicos para el tratamiento de trastornos neurodegenerativos.Info
- Publication number
- MX2016006052A MX2016006052A MX2016006052A MX2016006052A MX2016006052A MX 2016006052 A MX2016006052 A MX 2016006052A MX 2016006052 A MX2016006052 A MX 2016006052A MX 2016006052 A MX2016006052 A MX 2016006052A MX 2016006052 A MX2016006052 A MX 2016006052A
- Authority
- MX
- Mexico
- Prior art keywords
- halogen
- lower alkyl
- optionally substituted
- substituted
- hydroxy
- Prior art date
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 230000001272 neurogenic effect Effects 0.000 title 1
- UTPKXLXUFQVLKH-UHFFFAOYSA-N pyrido[3,4-b]pyrazine-2-carboxamide Chemical class N1=C2C(=NC=C1C(=O)N)C=NC=C2 UTPKXLXUFQVLKH-UHFFFAOYSA-N 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- -1 3,6-dihydro-pyran-4-yl Chemical group 0.000 abstract 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 102000014461 Ataxins Human genes 0.000 abstract 1
- 108010078286 Ataxins Proteins 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 206010008025 Cerebellar ataxia Diseases 0.000 abstract 1
- 208000027104 Chemotherapy-Related Cognitive Impairment Diseases 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 206010011878 Deafness Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 201000007737 Retinal degeneration Diseases 0.000 abstract 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000009205 Tinnitus Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 208000029560 autism spectrum disease Diseases 0.000 abstract 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 230000037326 chronic stress Effects 0.000 abstract 1
- 229960003920 cocaine Drugs 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000010370 hearing loss Effects 0.000 abstract 1
- 231100000888 hearing loss Toxicity 0.000 abstract 1
- 208000016354 hearing loss disease Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 229960001252 methamphetamine Drugs 0.000 abstract 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 abstract 1
- 229940127240 opiate Drugs 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 abstract 1
- 229950010883 phencyclidine Drugs 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 230000004258 retinal degeneration Effects 0.000 abstract 1
- 125000006413 ring segment Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000020431 spinal cord injury Diseases 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 231100000886 tinnitus Toxicity 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
Abstract
La presente invención se refiere a compuestos de la fórmula general: (ver Fórmula) en la que: R1 es hidrógeno, R2 es hidrógeno, alquilo inferior, bencilo, alquilo inferior sustituido con hidroxi o es cicloalquilo sustituido opcionalmente con ciano, o R1 y R2 forman, conjuntamente con el átomo de N al que se encuentran unidos, un grupo heterocicloalquilo, que opcionalmente contiene un átomo anular adicional de N, O o S, y que se encuentra sustituido opcionalmente con hidroxi, R3 es halógeno, fenilo sustituido opcionalmente con uno o más de halógeno, ciano, alquilo inferior sustituido con halógeno, alcoxi inferior sustituido con halógeno o con alquilo inferior sustituido con hidroxi, o es heteroarilo, sustituido opcionalmente con alquilo inferior o halógeno, o es 3,6-dihidro-pirán-4-ilo, o es piperidín-1-ilo sustituido opcionalmente con uno o más halógenos, o a una sal de adición de ácido farmacéuticamente aceptable, a una mezcla racémica o al enantiómero y/o isómero óptico correspondiente de los mismos. Los compuestos de fórmula I pueden utilizarse en el tratamiento de la esquizofrenia, el trastorno de personalidad obsesivo-compulsiva, la depresión mayor, los trastornos bipolares, los trastornos de ansiedad, el envejecimiento normal, la epilepsia, la degeneración retiniana, la lesión cerebral traumática, la lesión de la médula espinal, el trastorno de estrés post-traumático, el trastorno de pánico, la enfermedad de Parkinson, la demencia, la enfermedad de Alzheimer, las alteraciones cognitivas, la disfunción cognitiva inducida por quimioterapia, el síndrome de Down, los trastornos del espectro autista, la pérdida de audición, el tinnitus, la ataxia espinocerebelar, la esclerosis lateral amiotrófica, la esclerosis múltiple, la enfermedad de Huntington, el ictus, la terapia de radiación, el estrés crónico, el abuso de fármacos neuroactivos, seleccionados de entre el alcohol, los opiáceos, la metanfetamina, la fenciclidina y la cocaína.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13192406 | 2013-11-12 | ||
| PCT/EP2014/073988 WO2015071178A1 (en) | 2013-11-12 | 2014-11-07 | Pyrido[4,3-b]pyrazine-2-carboxamides as neurogenic agents for the treatment of neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016006052A true MX2016006052A (es) | 2016-07-18 |
Family
ID=49552255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016006052A MX2016006052A (es) | 2013-11-12 | 2014-11-07 | Pirido[4,3-b]pirazin-2-carboxamidas como agentes neurogenicos para el tratamiento de trastornos neurodegenerativos. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9670206B2 (es) |
| EP (1) | EP3068781B1 (es) |
| JP (1) | JP6229056B2 (es) |
| KR (1) | KR101861937B1 (es) |
| CN (1) | CN105764901B (es) |
| AU (1) | AU2014350371B2 (es) |
| CA (1) | CA2929461A1 (es) |
| CL (1) | CL2016001024A1 (es) |
| CR (1) | CR20160142A (es) |
| EA (1) | EA028940B1 (es) |
| IL (1) | IL244619A0 (es) |
| MA (1) | MA39027B1 (es) |
| MX (1) | MX2016006052A (es) |
| PE (1) | PE20160692A1 (es) |
| PH (1) | PH12016500605A1 (es) |
| UA (1) | UA117041C2 (es) |
| WO (1) | WO2015071178A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017072039A1 (de) | 2015-10-26 | 2017-05-04 | Bayer Cropscience Aktiengesellschaft | Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel |
| JP7491900B2 (ja) * | 2018-07-31 | 2024-05-28 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｔｌｒ７／８アンタゴニストおよびそれらの使用 |
| WO2020173861A1 (de) | 2019-02-26 | 2020-09-03 | Bayer Aktiengesellschaft | Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel |
| WO2020173860A1 (en) | 2019-02-26 | 2020-09-03 | Bayer Aktiengesellschaft | Fused bicyclic heterocycle derivatives as pesticides |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2575571A1 (en) * | 2004-08-03 | 2006-02-16 | Serenex, Inc. | 2,8-disubstituted naphthyridine derivatives |
| CN101356173B (zh) * | 2005-11-11 | 2012-10-31 | 阿特纳赞塔里斯有限公司 | 新的吡啶并吡嗪和它们作为激酶调节剂的用途 |
| WO2010101949A1 (en) | 2009-03-02 | 2010-09-10 | Sirtris Pharmaceuticals, Inc. | 8-substituted quinolines and related analogs as sirtuin modulators |
| WO2010124114A1 (en) * | 2009-04-22 | 2010-10-28 | Janssen Pharmaceutica Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
| CN103415289B (zh) * | 2010-07-07 | 2017-04-12 | 得克萨斯州大学系统董事会 | 前神经原性化合物 |
| CN105163727B (zh) * | 2013-05-03 | 2018-08-17 | 豪夫迈·罗氏有限公司 | 刺激神经发生的异喹啉衍生物 |
| TWI529171B (zh) * | 2013-07-29 | 2016-04-11 | 赫孚孟拉羅股份公司 | １，７－萘啶衍生物 |
-
2014
- 2014-11-07 JP JP2016530137A patent/JP6229056B2/ja not_active Expired - Fee Related
- 2014-11-07 CA CA2929461A patent/CA2929461A1/en not_active Abandoned
- 2014-11-07 MA MA39027A patent/MA39027B1/fr unknown
- 2014-11-07 AU AU2014350371A patent/AU2014350371B2/en not_active Ceased
- 2014-11-07 KR KR1020167012464A patent/KR101861937B1/ko not_active Expired - Fee Related
- 2014-11-07 EA EA201690971A patent/EA028940B1/ru not_active IP Right Cessation
- 2014-11-07 CN CN201480061521.6A patent/CN105764901B/zh not_active Expired - Fee Related
- 2014-11-07 MX MX2016006052A patent/MX2016006052A/es unknown
- 2014-11-07 UA UAA201606256A patent/UA117041C2/uk unknown
- 2014-11-07 EP EP14796743.4A patent/EP3068781B1/en not_active Not-in-force
- 2014-11-07 WO PCT/EP2014/073988 patent/WO2015071178A1/en not_active Ceased
- 2014-11-07 PE PE2016000545A patent/PE20160692A1/es unknown
-
2016
- 2016-03-16 IL IL244619A patent/IL244619A0/en unknown
- 2016-03-29 CR CR20160142A patent/CR20160142A/es unknown
- 2016-04-04 PH PH12016500605A patent/PH12016500605A1/en unknown
- 2016-04-29 CL CL2016001024A patent/CL2016001024A1/es unknown
- 2016-05-11 US US15/151,698 patent/US9670206B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN105764901A (zh) | 2016-07-13 |
| MA39027A1 (fr) | 2018-05-31 |
| AU2014350371B2 (en) | 2018-02-15 |
| IL244619A0 (en) | 2016-04-21 |
| EP3068781A1 (en) | 2016-09-21 |
| JP2016536320A (ja) | 2016-11-24 |
| HK1223916A1 (zh) | 2017-08-11 |
| CA2929461A1 (en) | 2015-05-21 |
| EA028940B1 (ru) | 2018-01-31 |
| EA201690971A1 (ru) | 2016-08-31 |
| CR20160142A (es) | 2016-05-04 |
| CN105764901B (zh) | 2018-06-22 |
| KR101861937B1 (ko) | 2018-05-28 |
| PE20160692A1 (es) | 2016-07-28 |
| KR20160061427A (ko) | 2016-05-31 |
| WO2015071178A1 (en) | 2015-05-21 |
| US9670206B2 (en) | 2017-06-06 |
| EP3068781B1 (en) | 2017-12-20 |
| US20160251355A1 (en) | 2016-09-01 |
| PH12016500605A1 (en) | 2016-06-13 |
| UA117041C2 (uk) | 2018-06-11 |
| CL2016001024A1 (es) | 2016-11-18 |
| JP6229056B2 (ja) | 2017-11-08 |
| MA39027B1 (fr) | 2018-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016008842A (es) | Derivados de n-fenil-lactama capaces de estimular la neurogenesis y su uso en el tratamiento de trastornos neurologicos. | |
| MX2016000895A (es) | Derivados de 1,7-naftiridina. | |
| AR093576A1 (es) | Derivados heterociclicos sustituidos | |
| MX2015006364A (es) | 1,6-naftiridinas sustituidas. | |
| MX2015015052A (es) | Derivados de isoquinolina que estimulan la neurogenesis. | |
| MX381925B (es) | Peliculas termocontraibles de barrera de multicapa pvdc. | |
| MX370661B (es) | Derivados de indolin-2-ona o pirrolo-piridin/pirimidin-2-ona. | |
| BR112015004942A2 (pt) | benzimidazóis como agentes ativos do snc | |
| MX375169B (es) | Derivados de indolin-2-ona o pirrolo-piridin-2-ona. | |
| PH12016500605A1 (en) | Pyrido[4,3-b]pyrazine-2-carboxamides as neurogenic agents for the treatment of neurodegenerative disorders | |
| MX2016008536A (es) | Derivados de fluoro-naftilo. | |
| BR112015008200A2 (pt) | derivados de imidazopiridina | |
| PH12015500059A1 (en) | Pieprazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one | |
| MX363461B (es) | Derivados de benzisoxazol como moduladores de la neurogénesis y el uso de los mismos en el tratamiento de enfermedades neurológicas y trastornos neuropsiquiátricos. | |
| MX2015013915A (es) | Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona. | |
| MX2016014845A (es) | Derivados indolin-2-ona y 1,3-dihidro-pirrol[3,2-c]piridin-2-ona. | |
| MX2016001528A (es) | Derivados de indol-carboxamida. | |
| TH165816A (th) | ไพริโด[4,3-b]ไพราซีน-2-คาร์บอกซาไมด์ ในรูปสารก่อกำเนิดประสาทสำหรับ การรักษาความผิดปกติที่มีภาวะเสื่อมของระบบประสาท |